Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Certolizumab Pegol

Criteria

Inclusion Criteria:

• Adult patient with established moderate to severe rheumatoid arthritis

Exclusion Criteria:

• All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment

• Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials